Masitinib for the Treatment of Alzheimer’s Disease
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symptoms. Masitinib is a potent and selective phenylaminothiazole-type tyrosine kinase inhibitor which is currently in Phase III studies for the treatment of Alzheimer's disease (AD) with the aim of modifying its evolution and with multiple pharmacological targets such as inhibition of mast cells activity, inhibition of microglia activation, modulation of Aβ and Tau protein signaling pathway and prevention of synaptic damage. Here, we review the preclinical and clinical studies that investigated the administration of masitinib treatment in monotherapy in AD. All research studies revealed positive effects concerning the cognitive functions in AD and generally with good safety and tolerability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Masitinib (28) is a potent and selective tyrosine kinase inhibitor targeting multiple aspects of AD, including inhibition of microglia and mast cell activation, modulation of Aβ and tau protein signaling pathways, and prevention of synaptic damage.475”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [475]
Citations
Cites
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Elmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Research works printed but not linked: 6
- 10.1186/s40478-020-00976-9 · DOI · Paper page
- 10.1371/journal.pone.0007258 · DOI · Paper page
- AB Science press release. (2020). https://www.ab-science.com/results-from-phase-2b-3-studyevaluating-masitinib-in-alzheimers-disease/
- 10.1523/JNEUROSCI.4162-03.2004 · DOI · Paper page
- 10.1523/JNEUROSCI.22-01-00010.2002 · DOI · Paper page
- 10.1016/j.cell.2010.06.036 · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics
Thakur, S., Dhapola, R., Sarma, P., Medhi, B., & Reddy, D. H. (2023) · Inflammation · doi:10.1007/s10753-022-01721-1 · Cited by 557
“A quadruple, double-blind, placebo study was carried out to evaluate the safety and efficacy of the drug [59].”
BackgroundKumari, S., Dhapola, R., Sharma, P., Singh, S. K., & HariKrishnaReddy, D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102098 · Cited by 58
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Zhang, Z., Gan, Q., Han, J., Tao, Q., Qiu, W. Q., & Madri, J. A. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231170041 · Cited by 39
“The src family kinase inhibitor saracatinib (vAZD0530) is the first effort to target Fyn, a member of the Scr family kinase, with a specific inhibitor, which was assessed favorably in a small phase II clinical trial in AD(122) and is currently in a phase III AD clinical trial.(123) It may provide a novel sight for reg…”
Background
Metadata
- Authors
- Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A.
- Affiliations
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Universitat Internacional de Catalunya (ES)
- Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Universitat de Barcelona (ES)
- Venue
- Neurodegenerative Disease Management
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- 11
- Issue
- 4
- Pages
- 263-276
- ISSN
- 1758-2024 (ISSN-L)
- 1758-2032
- OpenAlex
- W3194662903
- Cited by
- 28
- References
- 86
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurodegenerative Disease Management (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- masitinib, Alzheimer's disease, tyrosine kinase inhibitors, mast cell inhibition, microglial activation, amyloid-beta, tau protein, synaptic damage, cognitive function, drug safety and tolerability
- MeSH terms
- Alzheimer Disease, Benzamides, Cognition, Humans, Piperidines, Pyridines, Thiazoles, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Masitinib for the Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2217/nmt-2021-0019
- The paper
- Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A. (2021). Masitinib for the Treatment of Alzheimer’s Disease. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2021-0019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.